Search results
1 No-Brainer Dividend Stock Yielding More Than 5% to Buy and Hold Forever | The Motley Fool
The Motley Fool· 2 days agoWhen looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy....
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
Zacks· 3 days agoAstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
1 High-Yield ETF Could Turn $400 Per Month Into $50,000 In Annual Dividend Income
Motley Fool via Yahoo Finance· 17 hours agoDividend Equity ETF are: Texas Instruments (2.6% dividend yield) Amgen (2.9%) Lockheed Martin (2.7%)...
Pfizer (PFE) Recently Broke Out Above the 200-Day Moving Average
Zacks via Yahoo Finance· 4 days agoFrom a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a...
Pfizer targets $1.5 billion in savings by 2027 as it streamlines operations
WHTC 1450 Holland· 4 days ago(Reuters) -U.S. drugmaker Pfizer said on Wednesday it had launched a multi-year program to reduce...
Pfizer to Cut Costs in Multi-Year Effort
The Wall Street Journal· 4 days agoThe company said it estimates savings of $1.5 billion in the plan’s first phase by the end of 2027.
Pfizer Inc.’s latest rating changes from various analysts – Knox Daily
Knox Daily· 7 days agoPfizer Inc.’s recently made public that its Director Gottlieb Scott acquired Company’s shares for reported $79401.0 on Dec 15 ’23. In the deal valued at $26.47 per share,3,000 ...
Sen. Wyden questions Pfizer over tax rate as part of ongoing investigation
Endpoints News· 5 days agoSenate Finance Chair Ron Wyden (D-OR) is pressing Pfizer over its tax practices as part of his investigation into how large pharma companies use subsidiaries in other countries ...
Zantac not a cause of woman’s cancer, jury says in first trial over drug
Reuters via Yahoo News· 3 days agoA jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn...
HILL TAX BRIEF: Wyden Blasts Pfizer on International Tax Shifts
Bloomberg Law· 5 days agoSenate Finance Committee Chair Ron Wyden (D-Ore.) is expanding his investigation into profit-shifting practices of pharmaceutical companies with a new letter to drug powerhouse Pfizer.